Systemic Lupus Erythematosus Clinical Trial
Official title:
Effectiveness Study of Brief Group Psychoanalytic Psychotherapy (BGPP) to Improve Quality of Life in Patients With Systemic Lupus Erythematosus.
Psychosomatic is a new approach to understanding the phenomena of somatization using the
knowledge of medicine and psychology to treat human being. A Brief Group Psychanalytic
Psychotherapy (BGPP) for psychosomatic patients has been used to supplement the treatment of
some diseases including Systemic Lupus Erythematosus (SLE). The hypothesis of the study is
that BGPP beside clinical treatment can improve the quality of life and coping in SLE
patients. The aim of the study is to evaluate the effectiveness of BGPP in Brazilian SLE
patients.
Primary objective: To evaluate the effectiveness of BGPP to improve quality of life.
Secondary objectives: To evaluate the effectiveness of BGPP to improve coping, anxiety and
depression symptoms. SLE patients will be randomized to receive Psychotherapy or only
clinical treatment. The effectiveness will be assessed through specific questionnaires.
This is a prospective randomized clinical trial. Patients with SLE (ACR criteria, 1997)
treated at Rheumatology Division out-patient clinic of a university hospital were enrolled.
A sample of 80 patients was assessed at the beginning of the study (baseline) and will be
re-evaluated after 20 weeks (final) by clinical and psychological scales. Patients were
randomized by computer program and divided into experimental group (EG) and control group
(CG). Patients of both groups continued their medical treatment at the clinic. EG will be
treated with BGPP for 20 sessions once a week for 20 consecutive weeks in small groups. The
control group will be on a waiting list until the end of the study and will be treated
subsequently.
Inclusion criteria:
- Female gender
- Four or more ACR criteria for classification of SLE
- Age above 18 years
- Follow-up at the clinic for at least 6 months
Exclusion criteria :
- Illiterate patients
- Mental or physical comorbidities that compromise their participation
Evaluation:
The following scales (adapted and validated for Portuguese Language) were being applied for
a blinded evaluator to assess patients at baseline and after 20 weeks:
- Systemic Lupus International Disease Activity - SLEDAI Bombardier,1992);
- Systemic Symptom Checklist (SSC)(Freire, 2008);
- Systemic Lupus Erythematosus Quality of Life - SLEQOL (Freire, 2008);
- Coping strategies inventory of Folkman and Lazarus (Savoia,1996).
- Hospital Anxiety and Depression (Botega, 1995);
- Vital events scale of Holmes and Rahe (1967) (Savoia, 1995) and
Comparisons inter and intra groups were being analyzed using the Q square test for
categorical variables and Student's t test, Mann-Whitney, Wilcoxon or ANOVA for quantitative
variables. P values <0.05 will be considered as significant.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Health Services Research
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03843125 -
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
|
Phase 3 | |
Recruiting |
NCT05698173 -
Systemic Lupus Erythematosus and Accelerated Aging
|
N/A | |
Active, not recruiting |
NCT01649765 -
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
|
Phase 2 | |
Recruiting |
NCT05704153 -
Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A)
|
N/A | |
Completed |
NCT05048238 -
Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
|
Phase 1 | |
Recruiting |
NCT06056778 -
The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
|
||
Completed |
NCT04358302 -
Individual Patient Exposure and Response in Pediatric Lupus
|
N/A | |
Completed |
NCT03802578 -
The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients
|
N/A | |
Completed |
NCT02554019 -
Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT04835883 -
Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients
|
Phase 2 | |
Terminated |
NCT02665364 -
Phase IIb Study of IFN-K in Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT00278538 -
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT00069342 -
Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
|
||
Completed |
NCT03252587 -
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
|
Phase 2 | |
Terminated |
NCT02066311 -
Nelfinavir in Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT01892748 -
Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.
|
N/A | |
Terminated |
NCT01689025 -
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
Unknown status |
NCT01712529 -
Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients
|
N/A | |
Completed |
NCT01475149 -
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
|
N/A | |
Completed |
NCT00962832 -
A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus
|
Phase 2 |